氨溴索、布地奈德与异丙托溴铵联合治疗小儿支气管肺炎的效果分析

Effect analysis of combined treatment of ambroxol,budesonide and ipratropium bromide in children with bronchopneumonia

目的 评估氨溴索、布地奈德与异丙托溴铵联合治疗小儿支气管肺炎的临床疗效。方法 60例小儿支气管肺炎患儿,随机分为对照组与观察组,各30例。对照组予布地奈德联合异丙托溴铵雾化吸入治疗,观察组在对照组基础上联合氨溴索治疗。比较两组临床症状消失时间、治疗前后的炎性因子、临床疗效。结果 观察组咳嗽、气促、呼吸困难、喘鸣音消失时间分别为(3.14±1.07)、(4.26±1.14)、(2.12±0.76)、(4.72±1.26)d,均短于对照组的(4.59±1.19)、(5.79±1.23)、(3.03±0.91)、(6.03±1.45)d,差异有统计学意义(P<0.05)。治疗后,观察组超敏C反应蛋白(9.88±1.68)mg/L、白细胞介素-5(81.29±10.31)ng/L、血清降钙素原(3.20±0.51)μg/L均低于对照组的(13.02±1.95)mg/L、(107.47±12.03)ng/L、(4.73±0.63)μg/L,差异有统计学意义(P<0.05)。观察组治疗总有效率96.67%高于对照组的80.00%,差异有统计学意义(P<0.05)。结论 氨溴索、布地奈德与异丙托溴铵联合治疗小儿支气管肺炎效果优异,其能在最大化改善临床症状的基础上降低炎症反应,提升治愈速率。

Objective To evaluate the clinical efficacy of combined treatment of ambroxol,budesonide and ipratropium bromide in children with bronchopneumonia.Methods A total of 60 children with bronchopneumonia were randomly divided into control group and observation group,with 30 cases in each group.The control group was treated with budesonide and ipratropium bromide aerosol inhalation,and the observation group was treated with ambroxol on the basis of the control group.The disappearance time of clinical symptoms,inflammatory factors before and after treatment,and clinical efficacy were compared between the two groups.Results The disappearance time of cough,shortness of breath,dyspnea and wheezing in the observation group were(3.14±1.07),(4.26±1.14),(2.12±0.76) and(4.72±1.26) d,which were shorter than those of(4.59±1.19),(5.79±1.23),(3.03±0.91) and(6.03±1.45) d in the control group,and the differences were statistically significant(P0.05).After treatment,the observation group had high-sensitivity C-reactive protein of(9.88±1.68) mg/L,interleukin-5 of(81.29±10.31) ng/L and serum procalcitonin of(3.20±0.51) μg/L,which were lower than those of(13.02±1.95) mg/L,(107.47±12.03) ng/L and(4.73±0.63) μg/L in the control group,and the differences were significant(P0.05).The total effective rate of the observation group was 96.67%,which was higher than that of 80.00% of the control group,and the difference was statistically significant(P0.05).Conclusion The combined treatment of ambroxol,budesonide and ipratropium bromide has excellent effect in children with bronchopneumonia.It can reduce inflammatory reaction and improve the cure rate while maximizing the improvement of clinical symptoms.